Overview

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Status:
Completed
Trial end date:
2021-02-20
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis
Phase:
Phase 3
Details
Lead Sponsor:
Panion & BF Biotech Inc.
Collaborator:
Shandong Weigao Panion Pharmaceutical Co. Ltd.
Treatments:
Citric Acid
Ferric Compounds
Sevelamer
Sodium Citrate